Xanthus Pharmaceuticals, Inc. Appoints John Lister-James, Ph.D. As Vice President, Development
CAMBRIDGE, Mass., May 22 /PRNewswire/ -- Xanthus Pharmaceuticals, Inc., a privately-held oncology drug development company, today announced that John Lister-James, Ph.D. has joined the Xanthus management team as Vice President, Development.
"John brings to Xanthus a track record of approved products and advanced development projects, and is a recognized leader of multi-disciplinary R&D teams in the discovery and development of diagnostic and therapeutic products," stated Richard T. Dean, Ph.D., President and CEO of Xanthus. "We expect that John's expertise and broad skill-set will play a key role in the execution of our ongoing development programs in oncology and autoimmune therapeutics."
John Lister-James joins Xanthus from the Schering AG group where he was Vice President, Corporate CMC Development, Radiopharmaceuticals, at CIS-US, Inc. and responsible for Corporate Chemistry, Manufacturing and Controls (CMC) Development of radiopharmaceuticals. Previously, Dr. Lister-James was responsible for Research, CMC and Nonclinical Development and Clinical Research at Diatide Research Laboratories, a division of Berlex Laboratories (also a subsidiary of Schering AG). Prior to its acquisition by Berlex/Schering, Dr. Lister-James was Vice President, Science and Technology at Diatide, Inc. Earlier, Dr. Lister-James held technical and management positions at Centocor, where he supervised research and development of radiolabeled monoclonal antibodies. While at Diatide, Dr. Lister-James directed CMC/Nonclinical Development leading to the regulatory approval of NeoTect(R)/NeoSpect(TM) and AcuTect(R), and directed R&D activities leading to the discovery and early development of NeoTide(TM), a radiotherapeutic product for the treatment of lung cancer.
Dr. Lister-James obtained his Ph.D. in Organic Chemistry from the University of London and his B.Sc. (Honors) in Chemistry from Imperial College, University of London. He conducted post-doctoral work at the Massachusetts Institute of Technology and Harvard Medical School that focused on the chemistry of technetium and its application in medical imaging. He is a co-inventor of 60 U.S. patents and has co-authored over 35 peer-reviewed articles.
About Xanthus Pharmaceuticals, Inc.
Xanthus Pharmaceuticals, Inc. is developing a portfolio of novel, clinical-stage, small-molecule oncology candidates through a management team whose accomplished track record encompasses all aspects of drug development, from discovery through regulatory approval and commercialization. The Company is applying its expertise both to advance its current pipeline and expand it into indications of unmet medical need beyond oncology.
Xanthus is headquartered in Cambridge, Massachusetts with an additional facility in Montreal, Quebec. More information is available at http://www.xanthus.com.
Contacts: Kari Watson, MacDougall Biomedical Communications, Inc. - firstname.lastname@example.org or (508) 647-0209 Lisa Terry, Corporate Communications, Xanthus Pharmaceuticals, Inc. - email@example.com or (617) 252-6105Xanthus Pharmaceuticals, Inc.
CONTACT: Kari Watson of MacDougall Biomedical Communications, Inc.,+1-508-647-0209, firstname.lastname@example.org; or Lisa Terry, CorporateCommunications of Xanthus Pharmaceuticals, Inc., +1-617-252-6105,email@example.com
Web site: http://www.xanthus.com/